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Atherosclerotic renovascular disease (ARVD) is an
increasingly recognized clinical condition that is diagnosed
predominantly in older patients. Here we used annual United
States Medicare 5% Denominator Files and studied
16,036,904 patients, 66 years of age and older, to quantify
trends in diagnostic rates, associations, treatment, and
outcomes of ARVD over a 13-year period. Overall, there was
an ARVD rate of 3.09 per 1000 patient-years, which rose
progressively with an adjusted hazard ratio of 3.35,
comparing data from 1992 to 2004. Within 6 months of
disease diagnosis, 13.4% of patients had undergone
revascularization. A biphasic pattern of revascularization was
found where the adjusted hazard ratios significantly
increased in a progressive manner until 1999, following
which there was a decline through 2004, which was not
significant. The method of revascularization changed
markedly over time with endovascular intervention steadily
replacing direct surgical revascularization. As a time-
dependent variable, ARVD was associated with excess
mortality in each calendar year, albeit with declining hazard
ratio estimates in more recent years. Among patients with
this disease, revascularization was associated with mortality
adjusted hazard ratioso1 in each year. Our study shows the
diagnosis of ARVD has substantially risen in the United States
but the survival implications were not fully explained by
other comorbid vascular diseases.
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Atherosclerotic renovascular disease (ARVD), an increasingly
recognized clinical condition, is diagnosed predominantly in
older populations.1 It is believed to be more prevalent in
populations with hypertension, chronic kidney disease,
atherosclerotic heart disease, congestive cardiac failure,
peripheral vascular disease, and cerebrovascular disease,2–9
and these associations may be partly responsible for high
mortality rates associated with ARVD.10 Strategies with the
potential to alter the natural history of this condition are
currently being evaluated. Although clinical impression
suggests that the burden of ARVD is increasing, and ARVD
prevalence has risen considerably in patients starting renal
replacement therapy,11 few, if any, studies have attempted to
systematically address this hypothesis in general population
settings. The purpose of this study, therefore, was to quantify
trends in the diagnosis rates, associations, treatment, and
outcomes of ARVD in older US adults between 1992 and 2004.
RESULTS
Of the 16,036,904 study subjects, 48.9% were aged o75
years, 60.2% were women, and 88.6% were white (Table 1).
Over the course of the study, incidence of ARVD diagnosis
was 3.09 per 1000 patient-years. Regarding sources of
Medicare claim ascertainment for ARVD diagnosis, the
proportions from Part A (covering in-patient care in
hospitals, skilled nursing facilities, hospice, and home health
care) alone, for each year from 1992 to 2004, respectively,
were 31.45, 28.65, 25.33, 25.01, 24.32, 26.00, 25.07, 24.41,
24.28, 23.12, 20.44, 18.67, and 19.41; corresponding propor-
tions from Part B (covering outpatient care, physician
services, physical therapy, occupational therapy, and home
health care) alone were 43.65, 50.03, 49.63, 47.72, 47.56,
44.72, 44.49, 43.64, 44.46, 45.51, 46.64, 48.20, and 49.06; and
from Part A and Part B together, 24.90, 21.32, 25.04, 27.27,
28.12, 29.28, 30.43, 31.94, 31.26, 31.37, 32.92, 33.12, and
31.53. Hazard ratios for ARVD diagnosis rose progressively
by calendar year (Figure 1). For example, with 1992 as
reference category, unadjusted hazard ratios were 2.15 for
1997 and 4.71 for 2004. Findings were similar when
adjustment was made for baseline characteristics (Table 1),
except for moderate attenuation of hazard ratio estimates.
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Other characteristics associated with adjusted hazard ratios
(AHRs) 41.20 included chronic kidney disease (AHR 2.55),
hypertension (AHR 2.20), peripheral vascular disease (AHR
2.06), atherosclerotic heart disease (AHR 1.76), cerebrovas-
cular disease (AHR 1.31), diabetes mellitus (AHR 1.31), and
aortic aneurysm (AHR 1.28); AHR was o0.83 for age X85
(AHR 0.65), other race (AHR 0.71), and African-American
race (AHR 0.81).
Of the 47,719 patients diagnosed with ARVD, 6415
(13.4%) underwent revascularization within 6 months of
receiving the diagnosis. Compared with 1992, unadjusted
hazard ratios for revascularization rose progressively by
calendar year until 1999, thereafter declining progressively
until 2004 (Figure 2). Mean ages of patients with ARVD, for
each year from 1992 through 2004, respectively, were 74.79,
75.07, 75.09, 75.31, 75.63, 75.77, 75.84, 75.92, 76.10, 76.22,
76.32, 76.37, and 76.51 years. Findings were similar when
adjustment was made for baseline characteristics (Table 2),
except for moderate attenuation of hazard ratio estimates.
Characteristics associated with AHR 41.20 for revascular-
ization included hypertension (AHR 1.37) and atherosclero-
tic heart disease (AHR 1.27); AHR was o0.83 for age X85
(AHR 0.47), hepatic disease (AHR 0.69), African-American
race (AHR 0.71), other race (AHR 0.73), and malignancy
(AHR 0.82). The pattern of revascularization technique
changed markedly over time (Table 3), with endovascular
Table 1 | Baseline characteristics, 1992–2004 (n=16,036,904), and associations with future diagnosis of atherosclerotic
renovascular diseasea
Hazard ratio for ARVD (95% CI)
Characteristic Percentage Reference category Unadjusted P-value Adjusted P-value
Cohort year 1992
1992 8.07 1 — 1 —
1993 8.01 1.29 (1.20–1.38) o0.0001 1.26 (1.17–1.35) o0.0001
1994 8.10 1.41 (1.32–1.51) o0.0001 1.33 (1.25–1.43) o0.0001
1995 7.95 1.77 (1.65–1.88) o0.0001 1.62 (1.52–1.73) o0.0001
1996 7.72 1.91 (1.79–2.03) o0.0001 1.69 (1.58–1.80) o0.0001
1997 7.50 2.15 (2.01–2.29) o0.0001 1.85 (1.74–1.97) o0.0001
1998 7.30 2.44 (2.29–2.60) o0.0001 2.06 (1.94–2.19) o0.0001
1999 7.24 2.82 (2.66–3.00) o0.0001 2.33 (2.20–2.48) o0.0001
2000 7.27 3.21 (3.02–3.40) o0.0001 2.58 (2.43–2.74) o0.0001
2001 7.48 3.79 (3.58–4.02) o0.0001 2.94 (2.77–3.12) o0.0001
2002 7.70 4.07 (3.84–4.31) o0.0001 3.07 (2.89–3.25) o0.0001
2003 7.82 4.69 (4.43–4.97) o0.0001 3.44 (3.25–3.64) o0.0001
2004 7.85 4.71 (4.45–4.99) o0.0001 3.35 (3.17–3.55) o0.0001
Age, years 66–74
66–74 48.89 1 — 1 —
75–84 37.70 1.32 (1.30–1.35) o0.0001 1.05 (1.03–1.07) o0.0001
X85 13.41 0.91 (0.88–0.94) o0.0001 0.65 (0.63–0.67) o0.0001
Sex Men
Men 39.82 Women 1 — 1
Women 60.18 0.82 (0.80–0.83) o0.0001 0.87 (0.85–0.89) o0.0001
Race White
White 88.62 1 — 1 —
African American 7.44 0.96 (0.93–1.00) 0.03 0.81 (0.78–0.84) o0.0001
Other 3.94 0.79 (0.75–0.84) o0.0001 0.71 (0.68–0.75) o0.0001
Acute kidney injury 0.55 Absent 5.90 (5.57–6.24) o0.0001 1.05 (0.99–1.12) 0.1
CKD 1.56 Absent 6.61 (6.40–6.82) o0.0001 2.55 (2.46–2.65) o0.0001
Diabetes mellitus 15.05 Absent 2.33 (2.28–2.37) o0.0001 1.31 (1.28–1.33) o0.0001
Hypertension 41.10 Absent 3.37 (3.31–3.44) o0.0001 2.20 (2.15–2.25) o0.0001
ASHD 17.92 Absent 3.04 (2.99–3.10) o0.0001 1.76 (1.72–1.79) o0.0001
CHF 9.15 Absent 2.53 (2.47–2.59) o0.0001 1.10 (1.07–1.14) o0.0001
Cerebrovascular disease 7.46 Absent 2.49 (2.43–2.56) o0.0001 1.31 (1.28–1.35) o0.0001
Dysrhythmia 12.62 Absent 2.08 (2.04–2.13) o0.0001 1.03 (1.01–1.06) 0.01
PVD 8.17 Absent 3.50 (3.43–3.58) o0.0001 2.06 (2.01–2.11) o0.0001
COPD 10.46 Absent 1.75 (1.71–1.79) o0.0001 1.03 (1.01–1.06) 0.01
GI bleeding 3.29 Absent 1.74 (1.67–1.81) o0.0001 0.97 (0.93–1.01) 0.1
Hepatic disease 0.52 Absent 1.54 (1.39–1.71) o0.0001 0.89 (0.80–0.98) 0.02
Malignancy 8.65 Absent 1.26 (1.23–1.30) o0.0001 0.99 (0.96–1.02) 0.3
Anemia 9.76 Absent 2.15 (2.10–2.20) o0.0001 1.01 (1.07–1.13) o0.0001
Mesenteric ischemia 0.13 Absent 2.41 (2.04–2.84) o0.0001 1.07 (0.90–1.26) 0.5
Aortic aneurysm 0.25 Absent 3.67 (3.33–4.04) o0.0001 1.28 (1.16–1.41) o0.0001
ARVD, atherosclerotic renovascular disease; ASHD, atherosclerotic heart disease; CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease, GI, gastrointestinal; PVD, peripheral vascular disease.
aAll subjects were included. Cox regression was used to calculate hazard ratios for future diagnosis of ARVD. Adjustment was made for all variables shown in the first column.
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intervention (67.4% in 1992, 98.5% in 2004) steadily
replacing direct surgical revascularization. Surgical revascu-
larization was used for only 2.1% of revascularized patients in
2004. Among patients undergoing percutaneous revascular-
ization, the proportions who received stents, for each year
from 1992 through 2004, respectively, were 13.33, 27.27,
35.80, 48.11, 57.68, 63.01, 71.15, 71.96, 69.08, 69.73, 63.61,
68.51, and 67.61; corresponding proportions of patients who
did not receive stents were 86.67, 72.23, 64.20, 51.89, 42.32,
36.99, 28.85, 28.04, 30.92, 30.27, 36.39, 31.49, and 32.39.
Over a mean follow-up interval of 2.68 years, 2,487,580
study subjects (15.51%) died, a rate of 57.87 per 1000
patient-years. Figure 3 shows year-by-year trends in adjusted
mortality ratios for ARVD as a conditional event in the
overall study population, and for revascularization as a
conditional event in patients with ARVD. ARVD was
associated with excess mortality compared with the general
population in each calendar year, albeit with apparent
declines in hazard ratio estimates in more recent years.
Hazard ratios for mortality in ARVD patients undergoing
revascularization were o1 in each year; moderate year-to-
year variation was apparent, but there was no clear evidence
that hazard ratios had changed over time.
DISCUSSION
We observed a steady increase in ARVD diagnoses in US
patients aged 465 years, with likelihood of the diagnosis
3 times greater in 2002 than when the study began in 1992.
As this was a nonexperimental study based on administrative
claims, the relative contribution of increasing disease burden
and increased detection rates at earlier disease phases is
impossible to gauge. This being said, it is highly likely that
diagnostic modalities for ARVD improved between 1992
and 2004, with techniques such as ultrasound, computed
tomography, and magnetic resonance imaging facilitating
noninvasive ARVD detection. Related to this, the study era
prevented us from assessing whether rates of ARVD diag-
nosis have declined as a result of concern about gadolinium-
associated nephrogenic systemic fibrosis with magnetic
resonance imaging angiography.12,13 The associations of
ARVD with other major macrovascular pathologies, chronic
kidney disease, hypertension, and diabetes have been well-
described in recent large epidemiologic studies.10,11 As noted
in these studies, patients aged 485 years and those of races
other than white were less likely to be diagnosed with ARVD.
Even with extensive covariate adjustment in our study,
individuals of race or ethnicity other than white were less
likely to be diagnosed with ARVD, and, if they were
diagnosed, less likely to undergo revascularization. Although
a firm explanation cannot be established from our study, this
disparity suggests the possibility of nonmedical barriers to
appropriate investigation and care.
In the mid-to-late 1990s, use of renal revascularization to
treat ARVD increased, possibly coinciding with widespread
adoption of percutaneous renal angioplasty techniques.14
However, it was interesting to note the steady decline in
proportions of patients undergoing revascularization proce-
dures after 1999. This decline may reflect growing uncer-
tainty regarding appropriate management of ARVD,
particularly considering the lack of robust clinical trial
evidence to guide clinical practice.15 For example, we found
that, among patients diagnosed with ARVD, revascularization
was more likely from 1997 through 2000, with the return to
pre-1997 levels from 2001 to 2004. Interestingly, two
landmark studies were published in 1997 and 2000. The
former was a prospective study showing favorable outcomes
with intravascular stents in patients with critical ostial
stenoses,16 and the latter a randomized, controlled trial
showing that percutaneous transluminal renal angioplasty
had no long-term effect on blood pressure, antihypertensive
medication requirements, or kidney function among patients
with ARVD.17 Possibly, ARVD diagnoses through the 1990s
may have included a higher proportion of patients for whom
revascularization was considered inappropriate. Without
question, however, use of surgical revascularization techni-
ques to treat ARVD markedly decreased year on year
throughout the decade of the study, so that by 2004 more
than 97% of renal artery revascularization procedures were
performed percutaneously. This phenomenon, which has
been described previously among Medicare beneficiaries
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Figure 2 |Subjects diagnosed with atherosclerotic renovascular
disease: unadjusted hazard ratios, with 95% confidence
intervals, for revascularization within the ensuing 6 months by
calendar year, with 1992 as reference category. Po0.05; 1993,
P¼ 0.03; 1998, P¼ 0.002; 1999, P¼ 0.0004; 2000, P¼ 0.006.
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Figure 1 |Unadjusted hazard ratios, with 95% confidence
intervals, for atherosclerotic renovascular disease (ARVD) by
calendar year, with 1992 as reference category.
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Table 2 | Patients diagnosed with atherosclerotic renovascular disease: antecedent associations of revascularizationa
Hazard ratio for revascularization for ARVD (95% CI)
Characteristic Reference category Unadjusted P-value Adjusted P-value
Cohort year 1992
1992 1 — 1 —
1993 0.80 (0.65–0.98) 0.03 0.82 (0.66–1.00) 0.05
1994 0.86 (0.70–1.04) 0.1 0.87 (0.72–1.06) 0.2
1995 1.09 (0.91–1.30) 0.4 1.10 (0.91–1.32) 0.3
1996 1.08 (0.90–1.30) 0.4 1.09 (0.91–1.31) 0.3
1997 1.19 (1.00–1.42) 0.05 1.20 (1.01–1.43) 0.04
1998 1.31 (1.10–1.55) 0.002 1.32 (1.11–1.56) 0.002
1999 1.35 (1.14–1.60) 0.0004 1.35 (1.14–1.60) 0.0004
2000 1.26 (1.07–1.49) 0.006 1.27 (1.07–1.50) 0.005
2001 1.09 (0.93–1.29) 0.3 1.10 (0.93–1.29) 0.3
2002 1.11 (0.94–1.30) 0.2 1.11 (0.95–1.31) 0.2
2003 0.94 (0.80–1.11) 0.4 0.94 (0.80–1.11) 0.5
2004 0.86 (0.73–1.01) 0.06 0.86 (0.73–1.02) 0.08
Age, years 66–74
66–74 1 — 1 —
75–84 0.92 (0.87–0.96) 0.0007 0.90 (0.86–0.95) o0.0001
X85 0.47 (0.42–0.53) o0.0001 0.47 (0.42–0.53) o0.0001
Sex Men
Men Women 1 — 1 —
Women 1.04 (0.99–1.09) 0.1 1.06 (1.00–1.11) 0.04
Race White
White 1 — 1 —
African American 0.72 (0.65–0.81) o0.0001 0.71 (0.64–0.79) o0.0001
Other 0.73 (0.63–0.86) 0.0001 0.73 (0.62–0.86) 0.0001
Acute kidney injury Absent 0.98 (0.83–1.14) 0.8 1.07 (0.91–1.27) 0.4
CKD Absent 0.95 (0.87–1.04) 0.3 0.97 (0.88–1.07) 0.5
Diabetes mellitus Absent 0.98 (0.93–1.04) 0.5 0.93 (0.88–0.98) 0.009
Hypertension Absent 1.34 (1.27–1.42) o0.0001 1.37 (1.29–1.45) o0.0001
ASHD Absent 1.23 (1.17–1.29) o0.0001 1.27 (1.20–1.34) o0.0001
CHF Absent 0.95 (0.89–1.02) 0.1 0.96 (0.89–1.03) 0.3
Cerebrovascular disease Absent 1.18 (1.11–1.26) o0.0001 1.14 (1.07–1.22) 0.0001
Dysrhythmia Absent 0.92 (0.87–0.98) 0.01 0.89 (0.84–0.95) 0.0005
PVD Absent 1.03 (0.97–1.09) 0.4 0.99 (0.93–1.05) 0.7
COPD Absent 0.92 (0.86–0.99) 0.02 0.89 (0.83–0.96) 0.001
GI bleeding Absent 0.93 (0.83–1.04) 0.2 0.98 (0.87–1.10) 0.8
Hepatic disease Absent 0.67 (0.48–0.95) 0.03 0.69 (0.48–0.97) 0.04
Malignancy Absent 0.80 (0.73–0.87) o0.0001 0.82 (0.75–0.90) o0.0001
Anemia Absent 0.85 (0.79–0.90) o0.0001 0.85 (0.79–0.92) o0.0001
Mesenteric ischemia Absent 0.79 (0.48–1.32) 0.4 0.76 (0.46–1.26) 0.3
Aortic aneurysm Absent 0.92 (0.70–1.20) 0.5 0.87 (0.66–1.15) 0.3
ARVD, atherosclerotic renovascular disease; ASHD, atherosclerotic heart disease; CI, confidence interval; CHF, congestive heart failure; CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease, GI, gastrointestinal; PVD, peripheral vascular disease.
aAnalysis restricted to patients diagnosed with atherosclerotic renovascular disease. Cox regression was used to calculate hazard ratios for revascularization. Adjustment was
made for all variables shown in the first column.
Table 3 |Mode of revascularization for atherosclerotic renovascular disease by calendar year, with 1992 as reference category
Cohort year n Angioplasty/stent only, % Surgery only, % Angioplasty/stent and surgery, % P-value (vs 1992)
1992 178 64.61 32.58 2.81 —
1993 183 69.95 27.87 2.19 0.6
1994 217 72.35 25.35 2.30 0.3
1995 332 77.11 20.48 2.41 0.009
1996 347 83.00 15.56 1.44 o0.0001
1997 417 85.37 12.47 2.16 o0.0001
1998 508 89.57 7.87 2.56 o0.0001
1999 604 92.22 6.13 1.66 o0.0001
2000 650 95.08 4.46 0.46 o0.0001
2001 698 95.42 3.44 1.15 o0.0001
2002 781 97.18 2.18 0.64 o0.0001
2003 782 96.55 2.94 0.51 o0.0001
2004 718 97.91 1.53 0.56 o0.0001
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between 1996 and 2000,18 likely reflects the fact that tech-
nical outcomes are usually excellent with percutaneous
approaches, and procedure-related morbidity, mortality, and
hospitalization requirements may be lower than with surgical
intervention. Although mortality risk was higher for ARVD
patients than for the general Medicare population for each
cohort year, the adjusted risk progressively declined over time,
perhaps implying that earlier recognition (one major explanation
for the trend in increasing ARVD diagnoses) enabled earlier and
more effective vascular disease management. Revascularization
was associated with improved mortality risk in each ARVD
cohort year, but the influence of selection factors on this
treatment effect cannot be ascertained in this study.
Results of large, multicenter, randomized international
trials, designed to establish whether renal revascularization
can improve the major outcomes of renal functional stability
and patient mortality, are likely to influence the approach to
revascularization in the future. One recently published
multicenter, randomized, clinical trial compared the effect
of stent placement on renal function in patients with
creatinine clearance less than 80 ml/min per 1.73 m2 and
atherosclerotic renal artery stenosis of 450% who were
already receiving antihypertensive, statin, and aspirin ther-
apy. Stent placement had no effect on the evolution of renal
dysfunction. The authors suggest that a conservative medical
approach might be appropriate for most patients with ARVD,
given that stenting was occasionally followed by serious
clinical complications such as procedure-related death,
infected hematoma, and end-stage renal disease from
cholesterol embolism.19 Initial data reported from the
Angioplasty and STent for Renal Artery Lesions (ASTRAL)
trial,20 with more than 800 patients followed for a mean
period of 34 months, suggest that renal endovascular
revascularization with medical therapy provides no clinically
important benefit for renal function (the primary end point),
blood pressure, cardiac and renal events, or mortality,
compared with medical therapy alone. The Cardiovascular
Outcomes in Renal Atherosclerotic Lesions (CORAL) study21
has a different primary end point (a composite cardiovas-
cular and renal end point: cardiovascular or renal death,
myocardial infarction, hospitalization for congestive heart
failure, stroke, doubling of serum creatinine, and need for
renal replacement therapy), and is still recruiting patients.
Limitations of this study are that it was retrospective and
used administrative claims to define the study population
and outcomes. The accuracy of ARVD claims for ARVD
diagnosis could not be ascertained in this study. Conceivably,
ARVD may often have been an incidental finding during the
diagnostic work-up of patients with disease in nonrenal
vascular beds. The Medicare patient random samples that
we studied included older US populations, and caution
should be exercised in generalizing our findings to younger
populations or to other countries.
We believe that this study provides clinically important
information, particularly in relation to the evolution of
trends in clinician practice with respect to investigation and
management of this common condition. Notably, awareness
of increasing ARVD diagnoses, and of trends in use of
revascularization procedures, will be of interest to health-care
service providers. Results of the large international trials in
renovascular disease will further shape the epidemiology and
management of the condition in the future.
MATERIAL AND METHODS
Objectives
Among US adults agedX66 years, we set out to quantify the
following:
1. Trends in diagnosis rates of ARVD from 1992 through
2004, the primary objective.
2. Antecedent associations of ARVD.
3. Trends in revascularization for ARVD from 1992 through
2004.
4. Associations of revascularization for ARVD.
Patients and outcomes
In the United States, Medicare insurance coverage is universally
available from age 65 years. We used the United States
Medicare 5% Denominator File,22,23 a random sample based
on health insurance claim numbers. Major design features are
shown in Figure 4. Study subjects had the following
characteristics: continuous enrollment in Medicare Part A
and Part B from 1 January through 31 December of each study
year, 1992 to 2004; survival to 31 December of each calendar
year; aged X66 years on 31 December of each calendar year.
Patients enrolled in health maintenance organizations, with
Medicare as secondary payer; diagnosed with ARVD or end-
stage renal disease during the exposure period; or not residing
in the 50 US states, the District of Columbia, Puerto Rico, or
the Territories during each year were excluded.
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Figure 3 |Closed circles represent adjusted mortality hazard
ratios, with 95% confidence intervals, of atherosclerotic
renovascular disease (ARVD) in the overall population by
calendar year, with ARVD treated as a conditional, time-
dependent event. Po0.0001 for each calendar year. Open circles
represent mortality hazard ratios of ARVD revascularization in subjects
with ARVD by calendar year. Subjects diagnosed with ARVD (open
circles): adjusted, with ARVD revascularization treated as a conditional,
time-dependent event. Adjustment was made for all the
characteristics shown in the first column of Table 1. Po0.05; 1992,
P¼ 0.01; 1993, P¼ 0.01; 1996, P¼ 0.002; 1997, P¼ 0.005; 1998,
P¼ 0.04; 1999, P¼ 0.03; 2000, Po0.0001; 2001, P¼ 0.0006; 2002,
P¼ 0.0009.
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Baseline clinical characteristics were defined during the
1-year exposure periods using International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
and Current Procedural Terminology (CPT) codes, as shown
in the Appendix; codes for ARVD and renal revascularization
occurrence during the observation period are also shown.
ARVD and renal revascularization were defined by presence of
at least one ICD-9-CM or CPT procedural code. The specific
codes used to identify ARVD were 440.1 (atherosclerosis of
renal artery) and 593.81 (vascular disorders of kidney). Other
clinical conditions were defined by presence of one in-patient
hospitalization, skilled nursing facility, or home health agency
code, or two outpatient or physician/supplier codes less than 1
year apart, or one outpatient code and one physician/supplier
code less than 1 year apart.
Analysis
For ARVD ascertainment, patients in each annual cohort were
followed from 1 January of the succeeding year until the earliest
occurrence of ARVD diagnosis, death, renal replacement therapy,
change of health insurance payer status, or 31 December. For
example, for the 1992 cohort, ARVD occurrence was defined by
an appropriate ICD-9-CM or CPT code between 1 January 1992,
and 31 December 1993. For renal revascularization, follow-up
began at the first occurrence of ARVD and ended at the earliest
occurrence of an appropriate ICD-9-CM or CPT claim, death,
renal replacement therapy, change of health insurance payer
status, or 6 months. For mortality events, patients were followed
until the earliest occurrence of death, renal replacement therapy,
3 years, or 31 December 2006. Cox proportional hazard
modeling was used to quantify hazard ratios of baseline
population characteristics for time to ARVD occurrence and
revascularization after ARVD. As ARVD and revascularization
are conditional events that may not necessarily occur during the
follow-up period, these were treated as time-dependent variables
in Cox time-to-death models. SAS Version 9.1 (SAS Institute,
Cary, NC) was used for data assembly.
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1 January 1992
1 January 1993
Exposure period to define comorbidity
1 January 1993 31 December 1995
Follow-up period for death
Follow-up period to identify ARVD
31 December 1993
31 December 1992
Figure 4 |Definition of exposure and follow-up periods for
1992. ARVD, atherosclerotic renovascular disease.
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Appendix
International classification of diseases, ninth edition, clinical modification and current procedural terminology codes
International classification of diseases, ninth edition, clinical modification
Condition Diagnosis codes V codes Procedure codes
Current procedural terminology
codes
ASHD 410–414 V45.81;
V45.82
CHF 398.91; 425; 428; 402.X1; 404.x1;
404.x3
V42.1
CVA/TIA 430–438
PVD 440–444, except for 4401 and 4400;
447; 451–453
COPD 491–494; 496; 510
GI disease 456.0–456.2; 530.7; 531–534; 569.84;
569.85; 578
Liver disease 570; 571; 572.1; 572.4; 573.1–573.3 V42.7
Dysrhythmia 426–427 V45.0, V53.3
Diabetes mellitus 250; 357.2; 362.0x; 366.41
Cancer 140–172; 174–208; 230–231;
233–234
Anemia 280–285
CKD 250.4; 403.X1; 404.X2; 404.X3;
585–587; 794.4
Hypertension 362.11; 401.x–405.x; 437.2
AKD 584.x
Gut ischemia 557.0; 557.1; 557.9
Aortic aneurysm 440.0 39.71; 38.36; 38.44;
38.16
ARVD 440.1; 593.81
Renal
Revascularization
39.24; 38.10, 39.29,
39.50 2 weeks before
or after 88.45
35536
35636; 35560; 35450, 35471, 35631,
75966 with no prior 75726; 37205,
37206, 37207, 37208 with no prior
75726 and with 35450, 35471, or
75966 4 weeks prior
AKD, acute kidney disease; ARVD, atherosclerotic renovascular disease; ASHD, atherosclerotic heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident or transient ischemic attack; GI, gastrointestinal; PVD; peripheral vascular disease.
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